INJEX Pharma AG
INJEX Pharma AG: Changes in the prospectus schedule – decision on listing approval by the Frankfurt Stock Exchange and the commencement of share trading are postponed
INJEX Pharma AG / Key word(s): Miscellaneous Corporate News: Changes in the prospectus schedule – decision on listing approval by the Frankfurt Stock Exchange and the commencement of share trading are postponed Berlin, March 18, 2013 – INJEX Pharma AG announces that the timetable of the securities prospectus, that was approved on February 26, 2013, is changing. The approval decision of the Frankfurt Stock Exchange and the commencement of share trading which should have taken place today are postponed. According to the German Prospectus law, if a significant new factor arises during the relevant period, the company shall submit a supplementary prospectus containing details of the new factor to the Federal Financial Supervisory Authority (BaFin) for its approval. The relevant period begins when the prospectus is approved by the BaFin and ends when trading in the securities on the regulated market begins. After the approval of the prospectus on February 26th, 2013, a significant new factor arose which leads to a supplementary prospectus. The approval decision of the Frankfurt Stock Exchange and the commencement of share trading are postponed due to the obligation to write a supplementary prospectus. The postponement was initiated at the request of INJEX Pharma AG. INJEX Pharma AG will set up as fast as possible the supplementary prospectus. As long as the supplementary prospectus is not filed with BaFin, the approval decision of the Frankfurt Stock Exchange and the commencement of share trading will not take place. We endeavour to produce the draft within a reasonable timeframe, but more importantly will make sure, that all new events will be addressed appropriately. For further information on INJEX Pharma AG and its subsidiaries, please refer to www.injex.com. For further questions please contact our Investor Relations team directly: INJEX Pharma AG: End of Corporate News 18.03.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | INJEX Pharma AG | |
Buckower Damm 114 | ||
12349 Berlin | ||
Germany | ||
Phone: | +49 89 24 41 18 – 223 | |
Fax: | +49 89 24 41 18 – 499 | |
E-mail: | ir@injex.de | |
Internet: | www.injex.de | |
ISIN: | DE000A0STYL7 | |
WKN: | A0STYL | |
Listed: | Regulierter Markt in Frankfurt (General Standard) | |
Notierung vorgesehen / designated to be listed |
End of News | DGAP News-Service |
204253 18.03.2013 |